July 18, 2022
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including ongoing digitisation and the emergence of new types of liquid biopsies.
Medtech: Going steady explores these issues in more detail and reveals insights from the latest consensus forecasts out to 2028.
Look out for the Evaluate Vantage Medtech World Preview, coming soon.
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
September 5, 2024
Solid proof now exists that pharmacological intervention can help shift excess body weight. Yet, many questions remain, including: What’s the potential market size? How much is the pipeline worth? Which ...
August 19, 2024
Navigating the complex landscape of rare diseases requires a specialized approach. With over 7,000 types of rare diseases affecting more than 300 million people globally, and only a fraction having ...
August 12, 2024
Going into 2024, hopes were moderately high for dealmaking and the wider financial landscape in pharma. M&A and IPOs were picking up, offering investors the exit opportunities they need. But ...
Do the pharmaceutical industry’s billion-dollar drugs have an X-factor? To better understand the blockbuster landscape and identify the key characteristics driving their success, we’ve analysed Evaluate Pharma data on nearly ...
July 9, 2024
Last year’s Age of Uncertainty has given way to more predictable realities. Obesity drugs are set to dominate the 2030 forecasts, with more potent compounds, combinations, and oral formulations likely ...
After an Age of Uncertainty, the pharmaceutical industry is now shifting into a period with more predictable trends, where big pharma continues to focus on big drugs for big diseases. ...
